GLP-1 receptor agonists (Ozempic / Wegovy / Mounjaro)
Novo Nordisk; Eli Lilly (inventory-dependent)
Last checked Aug 21, 2026 · LawyerUnc editorial. Educational only, not legal advice.
Docket. MDL 3094 (E.D. Pa.)
Window LawyerUnc is tracking. 2018-01-01 → open
General causation
Plaintiffs allege failure to warn of gastroparesis, intestinal obstruction, and related gastric injuries. The drugs’ labels have evolved. General causation and adequacy of warning are actively litigated; a prescription is not a case.
Specific causation / screening
Typical screens look for a qualifying gastric diagnosis (not ordinary nausea), duration of use, and absence of a more likely alternative cause (uncontrolled diabetes, prior gastric surgery). Ileus and bowel obstruction are screened separately from garden-variety GI side effects.
Injuries currently screened
- Gastroparesis (diagnosed, not self-reported nausea)
- Ileus / intestinal obstruction
- Pulmonary aspiration associated with delayed gastric emptying (as alleged)
- Gallbladder injury in some inventories
Timeline
2017–2021
Approvals and uptake
Ozempic (2017), Wegovy (2021), Mounjaro (2022) drive a surge in off-label and on-label use.
2023
Label and safety communications
FDA and label updates address ileus and GI events. Plaintiff firms begin inventories.
2024
JPML centralization
MDL 3094 assigned to the Eastern District of Pennsylvania.
2025–2026
Discovery and science
Warning history, pharmacovigilance, and gastroenterology general-causation fights proceed.
Sources
- JPML MDL 3094
- FDA drug safety communications on GLP-1 RAs